Pivotal Phase 3 Trial for Pediatric Praziquantel Completes with Positive Results

PRESS RELEASE Corporate Announcements


Astellas Pharma Inc.

New pediatric formulation of Praziquantel, which Astellas Pharma Inc. (“Astellas”) provided its formulation technology and has been developed under the initiative of Merck together with its consortium partners, has now been completed its pivotal Phase 3 trial. The favorable results of this clinical trial allow the program to progress towards regulatory file submission to the European Medicines Agency (EMA).

Related News

Update on Regulatory Submission for Aducanumab in the European Union

Cambridge, Mass.– December 17, 2021 – Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the Committee for Medicinal P...



Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for the Treatment of HER2 Positive Advanced Gastric Cancer

Tokyo, Munich– (November 3, 2021) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the European Medicines Agency (EM...


PRESS RELEASE Corporate Announcements

EMA accepts regulatory submission for olipudase alfa, the first potential therapy for ASMD

The European Medicines Agency (EMA) has accepted for review under an accelerated assessment procedure the Marketing Authorization Application (MAA) fo...


PRESS RELEASE Research Findings

EMA Adopts a Positive CHMP Opinion for Pfizer’s and OPKO’s Somatrogon, a Long-Acting Treatment for Pediatric Growth Hormone Deficiency

NEW YORK, NY [December 17, 2021] - Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the Europ...


PRESS RELEASE Corporate Announcements

ASEC Frontier (Thailand) Co., Ltd

Address : 1 Empire Tower, Unit 1509,1710

15th,17th floor South Sathorn road Yannawa

Sathorn Bangkok, Thailand 10120

Tel : +662-118-0873

Email : info@medical-leaders-thailand.com

Website : www.asec-frontier.com


Contact Us